Literature DB >> 19669161

Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2.

Beate Betz1, Stephan Theiss, Murat Aktas, Carolin Konermann, Timm O Goecke, Gabriela Möslein, Heiner Schaal, Brigitte Royer-Pokora.   

Abstract

Hereditary non-polyposis colorectal cancer, an autosomal dominant predisposition to colorectal cancer and other malignancies, is caused by inactivating mutations of DNA mismatch repair genes, mainly MLH1 and MSH2. Missense mutations affect protein structure or function, but may also cause aberrant splicing, if located within splice sites (ss) or cis-acting sequences of splicing regulatory proteins, i.e., exonic splicing enhancers or exonic splicing silencers. Despite significant progress of ss scoring algorithms, the prediction for the impact of mutations on splicing is still unsatisfactory. For this study, we assessed ten ss and nine missense mutations outside ss in MLH1 and MSH2, including eleven newly identified mutations, and experimentally analyzed their effect at the RNA level. We additionally tested and compared the reliability of several web-based programs for the prediction of splicing outcome for these mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19669161     DOI: 10.1007/s00432-009-0643-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  Predictive identification of exonic splicing enhancers in human genes.

Authors:  William G Fairbrother; Ru-Fang Yeh; Phillip A Sharp; Christopher B Burge
Journal:  Science       Date:  2002-07-11       Impact factor: 47.728

2.  RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.

Authors:  Andrew Sharp; Gabriella Pichert; Anneke Lucassen; Diana Eccles
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

3.  Comparative analysis identifies exonic splicing regulatory sequences--The complex definition of enhancers and silencers.

Authors:  Amir Goren; Oren Ram; Maayan Amit; Hadas Keren; Galit Lev-Maor; Ida Vig; Tal Pupko; Gil Ast
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

4.  Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants.

Authors:  Constanze Pagenstecher; Maria Wehner; Waltraut Friedl; Nils Rahner; Stefan Aretz; Nicolaus Friedrichs; Marlies Sengteller; Wolfram Henn; Reinhard Buettner; Peter Propping; Elisabeth Mangold
Journal:  Hum Genet       Date:  2005-12-08       Impact factor: 4.132

5.  Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS3+3A>G mutation that causes exon skipping.

Authors:  Pia Pinholt Madsen; Maria Kibaek; Xavier Roca; Ravi Sachidanandam; Adrian R Krainer; Ernst Christensen; Robert D Steiner; K Michael Gibson; Thomas J Corydon; Inga Knudsen; Ronald J A Wanders; Jos P N Ruiter; Niels Gregersen; Brage Storstein Andresen
Journal:  Hum Genet       Date:  2005-11-30       Impact factor: 4.132

6.  Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption.

Authors:  K Wimmer; X Roca; H Beiglböck; T Callens; J Etzler; A R Rao; A R Krainer; C Fonatsch; L Messiaen
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

7.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals.

Authors:  Gene Yeo; Christopher B Burge
Journal:  J Comput Biol       Date:  2004       Impact factor: 1.479

8.  A novel approach to describe a U1 snRNA binding site.

Authors:  Marcel Freund; Corinna Asang; Susanne Kammler; Carolin Konermann; Jörg Krummheuer; Marianne Hipp; Imke Meyer; Wolfram Gierling; Stephan Theiss; Thorsten Preuss; Detlev Schindler; Jørgen Kjems; Heiner Schaal
Journal:  Nucleic Acids Res       Date:  2003-12-01       Impact factor: 16.971

9.  Aberrant 3' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.

Authors:  Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2006-09-08       Impact factor: 16.971

10.  In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 5' splice sites.

Authors:  Kentaro Sahashi; Akio Masuda; Tohru Matsuura; Jun Shinmi; Zhujun Zhang; Yasuhiro Takeshima; Masafumi Matsuo; Gen Sobue; Kinji Ohno
Journal:  Nucleic Acids Res       Date:  2007-08-28       Impact factor: 16.971

View more
  15 in total

Review 1.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

2.  Genomic HEXploring allows landscaping of novel potential splicing regulatory elements.

Authors:  Steffen Erkelenz; Stephan Theiss; Marianne Otte; Marek Widera; Jan Otto Peter; Heiner Schaal
Journal:  Nucleic Acids Res       Date:  2014-08-21       Impact factor: 16.971

3.  Correct mRNA processing at a mutant TT splice donor in FANCC ameliorates the clinical phenotype in patients and is enhanced by delivery of suppressor U1 snRNAs.

Authors:  Linda Hartmann; Kornelia Neveling; Stephanie Borkens; Hildegard Schneider; Marcel Freund; Elke Grassman; Stephan Theiss; Angela Wawer; Stefan Burdach; Arleen D Auerbach; Detlev Schindler; Helmut Hanenberg; Heiner Schaal
Journal:  Am J Hum Genet       Date:  2010-10-08       Impact factor: 11.025

4.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

5.  Familial Lynch syndrome with early age of onset and confirmed splice site mutation in MSH2: A case report.

Authors:  Zornitsa Bogomilova Kamburova; Savelina Lubenova Popovska; Katya Stefanova Kovacheva; Krasimir Todorov Petrov; Slavena Enkova Nikolova
Journal:  Biomed Rep       Date:  2022-03-14

6.  Genetic screens to identify pathogenic gene variants in the common cancer predisposition Lynch syndrome.

Authors:  Mark Drost; Anne Lützen; Sandrine van Hees; Daniel Ferreira; Fabienne Calléja; José B M Zonneveld; Finn Cilius Nielsen; Lene Juel Rasmussen; Niels de Wind
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-20       Impact factor: 11.205

7.  In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation.

Authors:  Ester Borras; Kyle Chang; Mala Pande; Amanda Cuddy; Jennifer L Bosch; Sarah A Bannon; Maureen E Mork; Miguel A Rodriguez-Bigas; Melissa W Taggart; Patrick M Lynch; Y Nancy You; Eduardo Vilar
Journal:  Cancer Prev Res (Phila)       Date:  2017-08-01

8.  RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease.

Authors:  Hui Y Xiong; Babak Alipanahi; Leo J Lee; Hannes Bretschneider; Daniele Merico; Ryan K C Yuen; Yimin Hua; Serge Gueroussov; Hamed S Najafabadi; Timothy R Hughes; Quaid Morris; Yoseph Barash; Adrian R Krainer; Nebojsa Jojic; Stephen W Scherer; Benjamin J Blencowe; Brendan J Frey
Journal:  Science       Date:  2014-12-18       Impact factor: 47.728

Review 9.  RNA splicing: a new player in the DNA damage response.

Authors:  Silvia C Lenzken; Alessia Loffreda; Silvia M L Barabino
Journal:  Int J Cell Biol       Date:  2013-09-12

10.  Cryptic splice sites and split genes.

Authors:  Yuri Kapustin; Elcie Chan; Rupa Sarkar; Frederick Wong; Igor Vorechovsky; Robert M Winston; Tatiana Tatusova; Nick J Dibb
Journal:  Nucleic Acids Res       Date:  2011-04-05       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.